Automated cell culture systems

01Overview and value chain#

Markers EC: EU GMP Annex 1 (ATMP manufacturing) | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU)

Automated cell culture systems replace the manual, technician-dependent steps of cell and gene therapy manufacturing — cell isolation, activation, transduction, expansion and formulation — with closed, robotically-operated platforms designed to cut cost, reduce operator-introduced variability and scale production beyond what a manual cleanroom process can support. The category spans full end-to-end manufacturing platforms that automate an entire cell-therapy production run inside a single closed system, robotics-driven modular manufacturing that automates specific high-touch steps (such as drug-product fill and finish) using standard collaborative robots, and the scheduling and orchestration software that coordinates multiple automated instruments into a single validated workflow. Demand is driven directly by the economics of cell-therapy manufacturing: a fully manual process is both expensive (cited cost reductions from automation reach 74% in one documented case) and difficult to scale to the patient volumes autologous and allogeneic cell therapies increasingly require, making automated systems a commercial necessity rather than an optional efficiency upgrade for cell-therapy developers and CDMOs.

The key directions of automated cell culture systems are:

End-to-end automated manufacturing platforms: closed systems that automate an entire cell-therapy production run — isolation through formulation — inside a single platform, positioned as an alternative to a traditional CDMO’s manual cleanroom process.
Robotics-driven modular manufacturing: collaborative-robot-based automation of specific high-touch manufacturing steps (drug-product handling, fill-finish) integrated into a broader manual or semi-automated process rather than replacing the entire workflow.
Workflow scheduling and orchestration software: software that coordinates multiple automated lab instruments (liquid handlers, incubators, analyzers) into a single scheduled, auditable workflow, the control layer above the physical automation hardware.
AI-assisted process control: software layers increasingly integrating AI agents and toolkits into the scheduling and execution layer, positioned as the “open execution layer” connecting automated lab hardware to AI-driven process decisions.

Sectoral value chain#

[Cell Source Material] ──> [Automated Isolation/Activation] ──> [Automated Expansion/Culture] ──> [Automated Formulation]
                                                    │
                                          (Workflow Scheduling/Orchestration)
                                                    │
                                                    ▼
[Patient-Ready Cell Product] <─── [QC and Release Testing] <─────┘

Fig. 1— Sectoral value chain

Value chain levels#

Level	Description	Key inputs/outputs
Cell source material	Patient (autologous) or donor (allogeneic) starting cell material entering the manufacturing process.	In: Apheresis material or donor cell source. Out: Source cells ready for isolation/activation.
Automated isolation/activation	Robotically isolating and activating the target cell population within a closed system.	In: Source cells. Out: Isolated, activated cell population.
Automated expansion/culture	Automated bioreactor or culture-vessel expansion of the activated cell population to manufacturing scale.	In: Activated cells. Out: Expanded cell population at target cell count.
Automated formulation	Robotically formulating the expanded cell population into the final drug-product format for fill-finish.	In: Expanded cell population. Out: Formulated drug product ready for fill-finish.
QC and release testing	Testing the formulated product against release specifications, increasingly scheduled and tracked through the same orchestration software as the manufacturing steps.	In: Formulated drug product. Out: QC-released or rejected batch.
Patient-ready cell product	The released, patient-ready autologous or allogeneic cell therapy product.	In: QC-released batch. Out: Patient-ready cell therapy product.

Table 1— Value chain levels

Cross-cutting technologies of the sector:

Closed cell-therapy automation: end-to-end automated platforms that keep the entire manufacturing process within a closed, robotically-operated system from isolation through formulation.
Robotic biomanufacturing cell line: collaborative-robot automation of specific high-touch manufacturing steps within a broader cell-therapy production line.
Lab workflow orchestration software: scheduling and coordination software that sequences multiple automated instruments into a single validated, auditable workflow.

02US#

The United States hosts two specialists at opposite ends of the automation spectrum: a full end-to-end closed-platform manufacturer and a modular robotics integrator, plus the orchestration-software layer coordinating automated instrument workflows more broadly.

End-to-end automated manufacturing, modular robotics, workflow orchestration software#

Cellares: operates the Cell Shuttle automated cell-therapy manufacturing platform within its “smart factory” (IDMO) model, with a documented case of first-patient dosing on product manufactured entirely on the platform for a partner’s cell therapy, positioned as an alternative to conventional CDMO manual manufacturing.
Multiply Labs: deploys collaborative-robot-driven automation for cell-therapy bio-manufacturing, with a documented 74% cost-reduction case study using Universal Robots cobots, targeting the specific high-touch manual steps within a broader manufacturing line rather than the entire process.
HighRes Biosolutions: produces the Cellario workflow-scheduling and orchestration software coordinating multiple automated lab instruments into a single scheduled workflow, recently extending the platform toward AI-agent integration (including an NVIDIA BioNeMo toolkit connection) as an “open execution layer” for automated lab operations.

03CN#

China’s presence in automated cell culture systems is limited to general lab-automation and cell-therapy manufacturing market coverage rather than a confirmed dedicated automation-platform producer: no domestic company’s own-domain page confirming a specific automated cell-culture manufacturing platform was found in this screen.

Market coverage only, no confirmed dedicated automation-platform producer#

General market visibility only: searches return industry reporting on China’s cell-therapy manufacturing capacity growth rather than a specific domestic company’s own commercial automated cell-culture platform.
No producer tabled: without an own-domain page confirming a specific Chinese company’s automated cell-culture manufacturing platform, none is listed here — an evidence gap to revisit as the category develops, not a claim that Chinese cell-therapy manufacturers are absent generally.

04EU#

Europe is represented by the UK specialist whose IRO platform recently earned a distinct FDA manufacturing-technology designation, evidence its automated approach is gaining regulatory as well as commercial traction.

Automated cell and gene therapy manufacturing, regulatory-designated platforms#

Ori Biotech (UK): operates the IRO automated cell and gene therapy manufacturing platform, which received FDA Advanced Manufacturing Technology (AMT) designation and has a documented strategic-partnership dosing milestone with a cell-therapy developer, positioning it alongside Cellares as a full-platform automated-manufacturing alternative to conventional CDMO processes.

05Leading companies and research institutes#

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
Cellares	🇺🇸 USA	Cell Shuttle, smart factories (IDMO)	End-to-end closed automated cell-therapy manufacturing	commercial
Ori Biotech	🇬🇧 UK	IRO platform	FDA Advanced Manufacturing Technology designation	commercial
Multiply Labs	🇺🇸 USA	Cobot-driven cell-therapy manufacturing automation	74% documented cost reduction using Universal Robots cobots	commercial
HighRes Biosolutions	🇺🇸 USA	Cellario OS workflow orchestration software	Multi-instrument scheduling, AI-agent integration (NVIDIA BioNeMo)	commercial

Table 2— Leading companies and research institutes

06Tech stack and innovations#

The stack spans full-platform hardware automation, modular robotics automation of specific steps, and the software orchestration layer that increasingly ties automated instruments into an AI-assisted control system.

End-to-End Closed Manufacturing Platforms:
- Cellares’s Cell Shuttle and Ori Biotech’s IRO platform both automate an entire cell-therapy manufacturing run inside a single closed system, the most capital-intensive but most comprehensive automation tier in the category.
- Both platforms have moved past pilot status to documented commercial traction — first-patient dosing on Cellares’s platform, and FDA AMT designation plus a partner dosing milestone for Ori Biotech — evidence the end-to-end approach has cleared real regulatory and manufacturing validation bars, not just demonstrated feasibility.
Modular Robotics Automation:
- Multiply Labs applies collaborative robots to specific high-touch manufacturing steps rather than automating the entire process, a lower-capital-intensity entry point that still delivers a documented, substantial cost reduction.
- This tier targets facilities retrofitting automation into an existing manual process rather than facilities building a fully automated line from scratch.
Workflow Orchestration and AI Integration:
- HighRes Biosolutions’s Cellario software sits above the physical automation hardware, scheduling and coordinating multiple instruments (liquid handlers, incubators, analyzers) into a single auditable workflow rather than automating a manufacturing step itself.
- The platform’s recent extension toward AI-agent integration, including a named NVIDIA toolkit connection, signals the orchestration layer is becoming the point where AI-driven process decisions get connected to physical lab automation, a distinct and newer commercial direction from the scheduling function alone.

07Value chains and production pipelines#

Industrial pipeline of an automated cell-therapy manufacturing run (FDA, EMA oversight)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Cell Source Material   │ ───> │ 2. Automated Isolation/Act.│
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Automated Formulation  │ <─── │ 3. Automated Expansion     │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. QC and Release Testing │ ───> │ 6. Patient-Ready Product   │
└───────────────────────────┘      └───────────────────────────┘

Fig. 2— Industrial pipeline of an automated cell-therapy manufacturing run (FDA, EMA oversight)

Stage 1: Cell source material

Patient (autologous) or donor (allogeneic) starting cell material enters the manufacturing process, the common starting point regardless of which automated platform processes it.

Stage 2: Automated isolation/activation

The target cell population is robotically isolated and activated within a closed system, eliminating the manual open-processing steps that introduce operator-dependent variability in conventional manufacturing.

Stage 3: Automated expansion/culture

The activated cell population is expanded to manufacturing scale within an automated bioreactor or culture-vessel system, scheduled and tracked by the platform’s orchestration layer.

Stage 4: Automated formulation

The expanded cell population is robotically formulated into its final drug-product format, the step immediately preceding fill-finish.

Stage 5: QC and release testing

The formulated product is tested against release specifications, increasingly scheduled and logged through the same orchestration software coordinating the upstream manufacturing steps.

Stage 6: Patient-ready cell product

The QC-released product moves forward as a patient-ready autologous or allogeneic cell therapy, the end point the entire automated manufacturing run was built to reach reliably and at scale.

Supplier	Region & tags
Cellares	US
Ori Biotech	EU
Multiply Labs	US
HighRes Biosolutions	US

AI Recommendation

Key directions:

Full-platform automation (Cellares, Ori Biotech) and modular robotic retrofitting (Multiply Labs) are different capital-intensity decisions, not two names for the same product — a facility already running a manual process is a better fit for the modular route, while a new-build facility is where a full closed platform makes more sense.
The orchestration-software layer (HighRes Biosolutions) is a separate purchasing decision from the physical automation hardware — it’s the scheduling brain that coordinates instruments, not a manufacturing platform itself, and is relevant even to a facility that hasn’t adopted end-to-end platform automation.
FDA Advanced Manufacturing Technology designation (held by Ori Biotech) is a real regulatory signal worth weighing separately from a vendor’s own marketing claims — it indicates the agency itself has recognized the manufacturing approach, not just that the company says its platform works.

Regulatory:

ATMP (advanced therapy medicinal product) manufacturing under EU GMP Annex 1 carries contamination-control and process-consistency expectations that closed automated platforms are specifically designed to satisfy — a facility evaluating manual-versus-automated shouldn’t treat this as a pure cost decision.
FDA’s AMT designation process is itself a signal worth tracking: a platform earning it has cleared agency-level scrutiny of the manufacturing technology, a different bar than a standard IND or BLA filing for the therapy itself.

Companies not in table:

Tecan was checked and dropped: the “Cellario” scheduling software actually belongs to HighRes Biosolutions, not Tecan — a company mix-up, not a genuine Tecan product, worth remembering since the two names get conflated in search results.
Sartorius and Thermo Fisher were checked in an earlier pass and dropped for scope mismatches: their confirmed evidence was a colony-picking/clone-selection instrument and a fill-finish system respectively, adjacent categories rather than automated cell culture itself.

Processing note:

No Chinese producer is listed: what surfaces is industry reporting on China’s growing cell-therapy manufacturing capacity, not a specific domestic company’s own automated-platform product page — worth re-checking as the category matures in that market.